COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
复制标题
DOI：
10.2807/1560-7917.es.2022.27.18.2200322
复制
发表时间：
2022-05
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
我们比较了2021年12月和2022年3月之间对严重新冠肺炎的疫苗有效性，当时欧米克龙BA.1和BA.2是瑞典斯卡尼亚县SARS-CoV-2的主要变异株。在至少接种了三剂疫苗的人中，从BA.1过渡到BA.2后，有效性保持在80%以上，但在只接种两剂疫苗的人中，点估计值显着下降到54%。在过渡到BA2之后，对先前感染的保护也较低。加强疫苗接种似乎对维持足够的保护是必要的。
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.